Metabolic reprogramming and redox adaptation in sorafenib-resistant leukemia cells: detected by untargeted metabolomics and stable isotope tracing analysis. View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-12

AUTHORS

Xin You, Weiye Jiang, Wenhua Lu, Hui Zhang, Tiantian Yu, Jingyu Tian, Shijun Wen, Guillermo Garcia-Manero, Peng Huang, Yumin Hu

ABSTRACT

BACKGROUND: Internal tandem duplications (ITD) within the juxtamembrane domain of FMS-like tyrosine kinase 3 (FLT3) represent a poor prognostic indicator in acute myeloid leukemia (AML). Therapeutic benefits of tyrosine kinase inhibitors, such as sorafenib, are limited due to the emergence of drug resistance. While investigations have been conducted to improve the understanding of the molecular mechanisms underlying the resistance to this FLT3 inhibitor, a profile of cell functioning at the metabolite level and crosstalk between metabolic pathways has yet to be created. This study aimed to elucidate the alteration of metabolomic profile of leukemia cells resistant to the FLT3 inhibitor. METHODS: We established two sorafenib-resistant cell lines carrying FLT3/ITD mutations, namely the murine BaF3/ITD-R and the human MV4-11-R cell lines. We performed a global untargeted metabolomics and stable isotope-labeling mass spectrometry analysis to identify the metabolic alterations relevant to the therapeutic resistance. RESULTS: The resistant cells displayed fundamentally rewired metabolic profiles, characterized by a higher demand for glucose, accompanied by a reduction in glucose flux into the pentose phosphate pathway (PPP); and by an increase in oxidative stress, accompanied by an enhanced glutathione synthesis. We demonstrated that the highest scoring network of altered metabolites in resistant cells was related to nucleotide degradation. A stable isotope tracing experiment was performed and the results indicated a decrease in the quantity of glucose entering the PPP in resistant cells. Further experiment suggested that the inhibition of major enzymes in the PPP consist of glucose-6-phosphate dehydrogenase deficiency (G6PD) in the oxidative arm and transketolase (TKT) in the non-oxidative arm. In addition, we observed that chronic treatment with sorafenib resulted in an increased oxidative stress in FLT3/ITD-positive leukemia cells, which was accompanied by decreased cell proliferation and an enhanced antioxidant response. CONCLUSIONS: Our data regarding comparative metabolomics characterized a distinct metabolic and redox adaptation that may contribute to sorafenib resistance in FLT3/ITD-mutated leukemia cells. More... »

PAGES

17

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s40880-019-0362-z

DOI

http://dx.doi.org/10.1186/s40880-019-0362-z

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1113184533

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30947742


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0601", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Biochemistry and Cell Biology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/06", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Biological Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "First Affiliated Hospital of Fujian Medical University", 
          "id": "https://www.grid.ac/institutes/grid.412683.a", 
          "name": [
            "Department of Experimental Therapeutics, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dong Feng East Road, Guangzhou, 510060, Guangdong, P. R. China.", 
            "The First Department of Chemotherapy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350005, Fujian, P. R. China."
          ], 
          "type": "Organization"
        }, 
        "familyName": "You", 
        "givenName": "Xin", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of Experimental Therapeutics, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dong Feng East Road, Guangzhou, 510060, Guangdong, P. R. China."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jiang", 
        "givenName": "Weiye", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of Experimental Therapeutics, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dong Feng East Road, Guangzhou, 510060, Guangdong, P. R. China."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lu", 
        "givenName": "Wenhua", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sun Yat-sen University", 
          "id": "https://www.grid.ac/institutes/grid.12981.33", 
          "name": [
            "Metabolic Innovation Center, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, Guangdong, P. R. China."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zhang", 
        "givenName": "Hui", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sun Yat-sen University", 
          "id": "https://www.grid.ac/institutes/grid.12981.33", 
          "name": [
            "Metabolic Innovation Center, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, Guangdong, P. R. China."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yu", 
        "givenName": "Tiantian", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of Experimental Therapeutics, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dong Feng East Road, Guangzhou, 510060, Guangdong, P. R. China."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tian", 
        "givenName": "Jingyu", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of Experimental Therapeutics, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dong Feng East Road, Guangzhou, 510060, Guangdong, P. R. China."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wen", 
        "givenName": "Shijun", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Garcia-Manero", 
        "givenName": "Guillermo", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sun Yat-sen University", 
          "id": "https://www.grid.ac/institutes/grid.12981.33", 
          "name": [
            "Department of Experimental Therapeutics, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dong Feng East Road, Guangzhou, 510060, Guangdong, P. R. China. huangpeng@sysucc.org.cn.", 
            "Metabolic Innovation Center, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, Guangdong, P. R. China. huangpeng@sysucc.org.cn."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Huang", 
        "givenName": "Peng", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sun Yat-sen University", 
          "id": "https://www.grid.ac/institutes/grid.12981.33", 
          "name": [
            "Department of Experimental Therapeutics, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dong Feng East Road, Guangzhou, 510060, Guangdong, P. R. China. huym@sysucc.org.cn.", 
            "Metabolic Innovation Center, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, Guangdong, P. R. China. huym@sysucc.org.cn."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hu", 
        "givenName": "Yumin", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1089/ars.2007.1957", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000616792"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.molcel.2014.09.024", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001477774"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.molcel.2014.09.024", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001477774"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1432-1033.1992.tb17420.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001962170"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/mrm.1910230215", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002274282"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/onc.2010.67", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003128990", 
          "https://doi.org/10.1038/onc.2010.67"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2014-10-605808", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005648199"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.tibs.2014.06.005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006864930"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/10408360500523878", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016862383"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1128/aem.02955-05", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019494531"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3324/haematol.2010.030452", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020137316"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4161/cbt.11.7.14948", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021919818"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature13236", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023194400", 
          "https://doi.org/10.1038/nature13236"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.cell.2011.02.013", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023540354"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.copbio.2015.02.003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023574034"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.celrep.2016.06.102", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029773766"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1152/ajpendo.00053.2007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036324261"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.canlet.2016.04.040", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046518091"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1012827221844", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047013523", 
          "https://doi.org/10.1023/a:1012827221844"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/onc.2010.273", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047102240", 
          "https://doi.org/10.1038/onc.2010.273"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/onc.2010.273", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047102240", 
          "https://doi.org/10.1038/onc.2010.273"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ctrv.2008.03.002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047994275"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2013.48.8783", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048989536"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079043980", 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2017.45", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083410265", 
          "https://doi.org/10.1038/leu.2017.45"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/bs.ircmb.2017.07.012", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1091846088"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-12", 
    "datePublishedReg": "2019-12-01", 
    "description": "BACKGROUND: Internal tandem duplications (ITD) within the juxtamembrane domain of FMS-like tyrosine kinase 3 (FLT3) represent a poor prognostic indicator in acute myeloid leukemia (AML). Therapeutic benefits of tyrosine kinase inhibitors, such as sorafenib, are limited due to the emergence of drug resistance. While investigations have been conducted to improve the understanding of the molecular mechanisms underlying the resistance to this FLT3 inhibitor, a profile of cell functioning at the metabolite level and crosstalk between metabolic pathways has yet to be created. This study aimed to elucidate the alteration of metabolomic profile of leukemia cells resistant to the FLT3 inhibitor.\nMETHODS: We established two sorafenib-resistant cell lines carrying FLT3/ITD mutations, namely the murine BaF3/ITD-R and the human MV4-11-R cell lines. We performed a global untargeted metabolomics and stable isotope-labeling mass spectrometry analysis to identify the metabolic alterations relevant to the therapeutic resistance.\nRESULTS: The resistant cells displayed fundamentally rewired metabolic profiles, characterized by a higher demand for glucose, accompanied by a reduction in glucose flux into the pentose phosphate pathway (PPP); and by an increase in oxidative stress, accompanied by an enhanced glutathione synthesis. We demonstrated that the highest scoring network of altered metabolites in resistant cells was related to nucleotide degradation. A stable isotope tracing experiment was performed and the results indicated a decrease in the quantity of glucose entering the PPP in resistant cells. Further experiment suggested that the inhibition of major enzymes in the PPP consist of glucose-6-phosphate dehydrogenase deficiency (G6PD) in the oxidative arm and transketolase (TKT) in the non-oxidative arm. In addition, we observed that chronic treatment with sorafenib resulted in an increased oxidative stress in FLT3/ITD-positive leukemia cells, which was accompanied by decreased cell proliferation and an enhanced antioxidant response.\nCONCLUSIONS: Our data regarding comparative metabolomics characterized a distinct metabolic and redox adaptation that may contribute to sorafenib resistance in FLT3/ITD-mutated leukemia cells.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s40880-019-0362-z", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1041144", 
        "issn": [
          "1000-467X", 
          "2523-3548"
        ], 
        "name": "Cancer Communications", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "39"
      }
    ], 
    "name": "Metabolic reprogramming and redox adaptation in sorafenib-resistant leukemia cells: detected by untargeted metabolomics and stable isotope tracing analysis.", 
    "pagination": "17", 
    "productId": [
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s40880-019-0362-z"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1113184533"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101723675"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30947742"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s40880-019-0362-z", 
      "https://app.dimensions.ai/details/publication/pub.1113184533"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-15T09:03", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000375_0000000375/records_91464_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://cancercommun.biomedcentral.com/articles/10.1186/s40880-019-0362-z"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s40880-019-0362-z'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s40880-019-0362-z'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s40880-019-0362-z'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s40880-019-0362-z'


 

This table displays all metadata directly associated to this object as RDF triples.

213 TRIPLES      21 PREDICATES      52 URIs      20 LITERALS      8 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s40880-019-0362-z schema:about anzsrc-for:06
2 anzsrc-for:0601
3 schema:author N28834702c3f74bc082e6c6263ea024b1
4 schema:citation sg:pub.10.1023/a:1012827221844
5 sg:pub.10.1038/leu.2017.45
6 sg:pub.10.1038/nature13236
7 sg:pub.10.1038/onc.2010.273
8 sg:pub.10.1038/onc.2010.67
9 https://app.dimensions.ai/details/publication/pub.1079043980
10 https://doi.org/10.1002/mrm.1910230215
11 https://doi.org/10.1016/bs.ircmb.2017.07.012
12 https://doi.org/10.1016/j.canlet.2016.04.040
13 https://doi.org/10.1016/j.cell.2011.02.013
14 https://doi.org/10.1016/j.celrep.2016.06.102
15 https://doi.org/10.1016/j.copbio.2015.02.003
16 https://doi.org/10.1016/j.ctrv.2008.03.002
17 https://doi.org/10.1016/j.molcel.2014.09.024
18 https://doi.org/10.1016/j.tibs.2014.06.005
19 https://doi.org/10.1080/10408360500523878
20 https://doi.org/10.1089/ars.2007.1957
21 https://doi.org/10.1111/j.1432-1033.1992.tb17420.x
22 https://doi.org/10.1128/aem.02955-05
23 https://doi.org/10.1152/ajpendo.00053.2007
24 https://doi.org/10.1182/blood-2014-10-605808
25 https://doi.org/10.1200/jco.2013.48.8783
26 https://doi.org/10.3324/haematol.2010.030452
27 https://doi.org/10.4161/cbt.11.7.14948
28 schema:datePublished 2019-12
29 schema:datePublishedReg 2019-12-01
30 schema:description BACKGROUND: Internal tandem duplications (ITD) within the juxtamembrane domain of FMS-like tyrosine kinase 3 (FLT3) represent a poor prognostic indicator in acute myeloid leukemia (AML). Therapeutic benefits of tyrosine kinase inhibitors, such as sorafenib, are limited due to the emergence of drug resistance. While investigations have been conducted to improve the understanding of the molecular mechanisms underlying the resistance to this FLT3 inhibitor, a profile of cell functioning at the metabolite level and crosstalk between metabolic pathways has yet to be created. This study aimed to elucidate the alteration of metabolomic profile of leukemia cells resistant to the FLT3 inhibitor. METHODS: We established two sorafenib-resistant cell lines carrying FLT3/ITD mutations, namely the murine BaF3/ITD-R and the human MV4-11-R cell lines. We performed a global untargeted metabolomics and stable isotope-labeling mass spectrometry analysis to identify the metabolic alterations relevant to the therapeutic resistance. RESULTS: The resistant cells displayed fundamentally rewired metabolic profiles, characterized by a higher demand for glucose, accompanied by a reduction in glucose flux into the pentose phosphate pathway (PPP); and by an increase in oxidative stress, accompanied by an enhanced glutathione synthesis. We demonstrated that the highest scoring network of altered metabolites in resistant cells was related to nucleotide degradation. A stable isotope tracing experiment was performed and the results indicated a decrease in the quantity of glucose entering the PPP in resistant cells. Further experiment suggested that the inhibition of major enzymes in the PPP consist of glucose-6-phosphate dehydrogenase deficiency (G6PD) in the oxidative arm and transketolase (TKT) in the non-oxidative arm. In addition, we observed that chronic treatment with sorafenib resulted in an increased oxidative stress in FLT3/ITD-positive leukemia cells, which was accompanied by decreased cell proliferation and an enhanced antioxidant response. CONCLUSIONS: Our data regarding comparative metabolomics characterized a distinct metabolic and redox adaptation that may contribute to sorafenib resistance in FLT3/ITD-mutated leukemia cells.
31 schema:genre research_article
32 schema:inLanguage en
33 schema:isAccessibleForFree true
34 schema:isPartOf N1cfa5feaac884db5a4a04870acb53201
35 Nfd852bebe96a4bceaddf3a2849add931
36 sg:journal.1041144
37 schema:name Metabolic reprogramming and redox adaptation in sorafenib-resistant leukemia cells: detected by untargeted metabolomics and stable isotope tracing analysis.
38 schema:pagination 17
39 schema:productId N157620dca436413e835864f1aafd3ce5
40 N3e903c04efbf478aa7017b043c0028c8
41 N3f12052b4ea249a88f16aab825332962
42 N5bb6c940fc984b20977c33f5b9e6f3a1
43 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113184533
44 https://doi.org/10.1186/s40880-019-0362-z
45 schema:sdDatePublished 2019-04-15T09:03
46 schema:sdLicense https://scigraph.springernature.com/explorer/license/
47 schema:sdPublisher Na093ab0943b0491497d58f9b71301f37
48 schema:url https://cancercommun.biomedcentral.com/articles/10.1186/s40880-019-0362-z
49 sgo:license sg:explorer/license/
50 sgo:sdDataset articles
51 rdf:type schema:ScholarlyArticle
52 N04154383d401409292548c297faad090 schema:affiliation N9a03a53dd2c046cf80e81a2f13b97e98
53 schema:familyName Tian
54 schema:givenName Jingyu
55 rdf:type schema:Person
56 N0e03ae28fd4c478aab04241007618f00 rdf:first N50f05070460f421497ba2a2fbb7aae89
57 rdf:rest Nadefc391698140d9b11a4ce48a4fed76
58 N0e33c10c68f948bab76fd3524b9bd71b schema:affiliation https://www.grid.ac/institutes/grid.412683.a
59 schema:familyName You
60 schema:givenName Xin
61 rdf:type schema:Person
62 N11e9680cfad444b4be9d4b1f0b606f1a schema:affiliation Na35e495406154cc791e63a033c242c7e
63 schema:familyName Lu
64 schema:givenName Wenhua
65 rdf:type schema:Person
66 N157620dca436413e835864f1aafd3ce5 schema:name dimensions_id
67 schema:value pub.1113184533
68 rdf:type schema:PropertyValue
69 N1cfa5feaac884db5a4a04870acb53201 schema:issueNumber 1
70 rdf:type schema:PublicationIssue
71 N28834702c3f74bc082e6c6263ea024b1 rdf:first N0e33c10c68f948bab76fd3524b9bd71b
72 rdf:rest N3d8a06cc709a4e1685ec9fa686f820a9
73 N3d8a06cc709a4e1685ec9fa686f820a9 rdf:first Nb3cd69a7ed3047b2b66d84259ebe016a
74 rdf:rest N43a8f0fa34f34c76b5ca9811c74135f9
75 N3e903c04efbf478aa7017b043c0028c8 schema:name nlm_unique_id
76 schema:value 101723675
77 rdf:type schema:PropertyValue
78 N3f12052b4ea249a88f16aab825332962 schema:name doi
79 schema:value 10.1186/s40880-019-0362-z
80 rdf:type schema:PropertyValue
81 N43a8f0fa34f34c76b5ca9811c74135f9 rdf:first N11e9680cfad444b4be9d4b1f0b606f1a
82 rdf:rest Nd2e240ac68ce4d9e8c019837a61cce4e
83 N50f05070460f421497ba2a2fbb7aae89 schema:affiliation N50f65b68c71048af9a0f22c756836e8c
84 schema:familyName Wen
85 schema:givenName Shijun
86 rdf:type schema:Person
87 N50f65b68c71048af9a0f22c756836e8c schema:name Department of Experimental Therapeutics, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dong Feng East Road, Guangzhou, 510060, Guangdong, P. R. China.
88 rdf:type schema:Organization
89 N587bd3f7b96a4ada8ef4030d0b5d724d rdf:first Nb58ca59660a54faf8e3cfb2e362d759c
90 rdf:rest N77cead4e6cd44d029641d0a1bc40b9b0
91 N5bb6c940fc984b20977c33f5b9e6f3a1 schema:name pubmed_id
92 schema:value 30947742
93 rdf:type schema:PropertyValue
94 N776e71d764da45f2a16e3ca027bff2dd rdf:first N91e60c10d77546f989a24741f1b91511
95 rdf:rest N954bcd3e27974c4ba78013a03bd883f3
96 N77cead4e6cd44d029641d0a1bc40b9b0 rdf:first N04154383d401409292548c297faad090
97 rdf:rest N0e03ae28fd4c478aab04241007618f00
98 N82d847cd613642109399900cdeaf7632 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
99 schema:familyName Garcia-Manero
100 schema:givenName Guillermo
101 rdf:type schema:Person
102 N91e60c10d77546f989a24741f1b91511 schema:affiliation https://www.grid.ac/institutes/grid.12981.33
103 schema:familyName Huang
104 schema:givenName Peng
105 rdf:type schema:Person
106 N954bcd3e27974c4ba78013a03bd883f3 rdf:first Nc05acb23515942adbeb117ae32c17f93
107 rdf:rest rdf:nil
108 N9a03a53dd2c046cf80e81a2f13b97e98 schema:name Department of Experimental Therapeutics, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dong Feng East Road, Guangzhou, 510060, Guangdong, P. R. China.
109 rdf:type schema:Organization
110 Na093ab0943b0491497d58f9b71301f37 schema:name Springer Nature - SN SciGraph project
111 rdf:type schema:Organization
112 Na35e495406154cc791e63a033c242c7e schema:name Department of Experimental Therapeutics, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dong Feng East Road, Guangzhou, 510060, Guangdong, P. R. China.
113 rdf:type schema:Organization
114 Na5880900e91e4206b99cfd649c544f5a schema:affiliation https://www.grid.ac/institutes/grid.12981.33
115 schema:familyName Zhang
116 schema:givenName Hui
117 rdf:type schema:Person
118 Nadefc391698140d9b11a4ce48a4fed76 rdf:first N82d847cd613642109399900cdeaf7632
119 rdf:rest N776e71d764da45f2a16e3ca027bff2dd
120 Nb3cd69a7ed3047b2b66d84259ebe016a schema:affiliation Nce4cc52c50e54523b8ea683f687c83a4
121 schema:familyName Jiang
122 schema:givenName Weiye
123 rdf:type schema:Person
124 Nb58ca59660a54faf8e3cfb2e362d759c schema:affiliation https://www.grid.ac/institutes/grid.12981.33
125 schema:familyName Yu
126 schema:givenName Tiantian
127 rdf:type schema:Person
128 Nc05acb23515942adbeb117ae32c17f93 schema:affiliation https://www.grid.ac/institutes/grid.12981.33
129 schema:familyName Hu
130 schema:givenName Yumin
131 rdf:type schema:Person
132 Nce4cc52c50e54523b8ea683f687c83a4 schema:name Department of Experimental Therapeutics, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dong Feng East Road, Guangzhou, 510060, Guangdong, P. R. China.
133 rdf:type schema:Organization
134 Nd2e240ac68ce4d9e8c019837a61cce4e rdf:first Na5880900e91e4206b99cfd649c544f5a
135 rdf:rest N587bd3f7b96a4ada8ef4030d0b5d724d
136 Nfd852bebe96a4bceaddf3a2849add931 schema:volumeNumber 39
137 rdf:type schema:PublicationVolume
138 anzsrc-for:06 schema:inDefinedTermSet anzsrc-for:
139 schema:name Biological Sciences
140 rdf:type schema:DefinedTerm
141 anzsrc-for:0601 schema:inDefinedTermSet anzsrc-for:
142 schema:name Biochemistry and Cell Biology
143 rdf:type schema:DefinedTerm
144 sg:journal.1041144 schema:issn 1000-467X
145 2523-3548
146 schema:name Cancer Communications
147 rdf:type schema:Periodical
148 sg:pub.10.1023/a:1012827221844 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047013523
149 https://doi.org/10.1023/a:1012827221844
150 rdf:type schema:CreativeWork
151 sg:pub.10.1038/leu.2017.45 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083410265
152 https://doi.org/10.1038/leu.2017.45
153 rdf:type schema:CreativeWork
154 sg:pub.10.1038/nature13236 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023194400
155 https://doi.org/10.1038/nature13236
156 rdf:type schema:CreativeWork
157 sg:pub.10.1038/onc.2010.273 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047102240
158 https://doi.org/10.1038/onc.2010.273
159 rdf:type schema:CreativeWork
160 sg:pub.10.1038/onc.2010.67 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003128990
161 https://doi.org/10.1038/onc.2010.67
162 rdf:type schema:CreativeWork
163 https://app.dimensions.ai/details/publication/pub.1079043980 schema:CreativeWork
164 https://doi.org/10.1002/mrm.1910230215 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002274282
165 rdf:type schema:CreativeWork
166 https://doi.org/10.1016/bs.ircmb.2017.07.012 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091846088
167 rdf:type schema:CreativeWork
168 https://doi.org/10.1016/j.canlet.2016.04.040 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046518091
169 rdf:type schema:CreativeWork
170 https://doi.org/10.1016/j.cell.2011.02.013 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023540354
171 rdf:type schema:CreativeWork
172 https://doi.org/10.1016/j.celrep.2016.06.102 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029773766
173 rdf:type schema:CreativeWork
174 https://doi.org/10.1016/j.copbio.2015.02.003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023574034
175 rdf:type schema:CreativeWork
176 https://doi.org/10.1016/j.ctrv.2008.03.002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047994275
177 rdf:type schema:CreativeWork
178 https://doi.org/10.1016/j.molcel.2014.09.024 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001477774
179 rdf:type schema:CreativeWork
180 https://doi.org/10.1016/j.tibs.2014.06.005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006864930
181 rdf:type schema:CreativeWork
182 https://doi.org/10.1080/10408360500523878 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016862383
183 rdf:type schema:CreativeWork
184 https://doi.org/10.1089/ars.2007.1957 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000616792
185 rdf:type schema:CreativeWork
186 https://doi.org/10.1111/j.1432-1033.1992.tb17420.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1001962170
187 rdf:type schema:CreativeWork
188 https://doi.org/10.1128/aem.02955-05 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019494531
189 rdf:type schema:CreativeWork
190 https://doi.org/10.1152/ajpendo.00053.2007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036324261
191 rdf:type schema:CreativeWork
192 https://doi.org/10.1182/blood-2014-10-605808 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005648199
193 rdf:type schema:CreativeWork
194 https://doi.org/10.1200/jco.2013.48.8783 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048989536
195 rdf:type schema:CreativeWork
196 https://doi.org/10.3324/haematol.2010.030452 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020137316
197 rdf:type schema:CreativeWork
198 https://doi.org/10.4161/cbt.11.7.14948 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021919818
199 rdf:type schema:CreativeWork
200 https://www.grid.ac/institutes/grid.12981.33 schema:alternateName Sun Yat-sen University
201 schema:name Department of Experimental Therapeutics, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dong Feng East Road, Guangzhou, 510060, Guangdong, P. R. China. huangpeng@sysucc.org.cn.
202 Department of Experimental Therapeutics, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dong Feng East Road, Guangzhou, 510060, Guangdong, P. R. China. huym@sysucc.org.cn.
203 Metabolic Innovation Center, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, Guangdong, P. R. China.
204 Metabolic Innovation Center, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, Guangdong, P. R. China. huangpeng@sysucc.org.cn.
205 Metabolic Innovation Center, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, Guangdong, P. R. China. huym@sysucc.org.cn.
206 rdf:type schema:Organization
207 https://www.grid.ac/institutes/grid.240145.6 schema:alternateName The University of Texas MD Anderson Cancer Center
208 schema:name Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA.
209 rdf:type schema:Organization
210 https://www.grid.ac/institutes/grid.412683.a schema:alternateName First Affiliated Hospital of Fujian Medical University
211 schema:name Department of Experimental Therapeutics, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dong Feng East Road, Guangzhou, 510060, Guangdong, P. R. China.
212 The First Department of Chemotherapy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350005, Fujian, P. R. China.
213 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...